ALTERNATIVES

Instead of Just a PSA Test, Try These

The standard PSA blood test misses aggressive cancers, flags slow-growing ones that never needed treatment, and sends 75% of men with elevated results to unnecessary biopsies. Here's what smart screening actually looks like.

Why PSA Alone Isn't Enough

75%
False positive biopsies
50%
Overdiagnosis rate
2.4×
More biopsies needed

The PSA (Prostate-Specific Antigen) blood test has been the default screening tool since the 1990s. It measures a protein produced by the prostate — but elevated levels don't necessarily mean cancer. Enlarged prostate (BPH), recent sexual activity, exercise, and even riding a bicycle can spike PSA levels, according to AUA guidelines.

Here's the math that matters: for every 1,000 men screened with PSA alone, roughly 100–120 will have elevated results. Of those, about 75% will undergo a biopsy that reveals no cancer — a painful, expensive procedure with real risks including infection and bleeding. Meanwhile, PSA can miss aggressive cancers entirely in men whose levels appear normal, reports research published in the New England Journal of Medicine.

The PLCO Cancer Screening Trial followed 76,693 men for 13 years and found no significant reduction in prostate cancer mortality from PSA screening alone. The European Randomized Study of Screening for Prostate Cancer (ERSPC) showed a 21% mortality reduction — but at the cost of diagnosing and treating many men whose cancers would never have become life-threatening. The USPSTF currently recommends shared decision-making for men 55–69, acknowledging the test's significant limitations.

The real problem isn't that PSA exists — it's that most men and many doctors treat it as the final answer rather than one incomplete data point. The alternatives below give you a much clearer picture.

Smarter Screening Approaches

Each one fills the gaps PSA leaves behind. Most work best combined with PSA — not instead of it entirely.

Prostate Health Index (PHI)

$150–$250
Why instead: Combines total PSA, free PSA, and [-2]proPSA into one score — 2.5× more specific for aggressive cancer than PSA alone. Catches what PSA misses without the false alarm rate.
Learn More

Multi-Parametric MRI (mpMRI)

$500–$1,500
Why instead: Directly visualizes suspicious lesions before any biopsy needle enters your body. Studies show mpMRI-first screening reduces unnecessary biopsies by 27% while detecting more clinically significant cancers.
Learn More

4Kscore Test

$200–$400
Why instead: Measures four kallikrein markers in blood to predict your risk of aggressive (Gleason ≥7) cancer specifically. Reduces unnecessary biopsies by ~60% — you only go under the needle when it's truly warranted.
Learn More

Genetic Risk Assessment

$250–$500
Why instead: Analyzes 170+ genetic variants to generate a personalized polygenic risk score. Tells you whether you need more frequent, more aggressive screening — or can safely relax. No other test personalizes your timeline like this.
Learn More

When PSA Still Makes Sense

PSA isn't useless — it's just incomplete. Get a PSA test if you have a strong family history (father or brother diagnosed with prostate cancer), if you're African American (who face 1.7× higher incidence), or if you've had an abnormal digital rectal exam. In these cases, PSA is a reasonable starting point — but it should never be the only data point.

For everyone else: if your doctor orders only a PSA test and calls it screening, ask about PHI, mpMRI, or the 4Kscore. A urologist who uses these tools alongside PSA is giving you a real screening workup — not just checking a box. The goal isn't to avoid PSA entirely. It's to stop treating one incomplete number as the whole story.

We Research So You Don't Have To

Get evidence-based prostate health updates from Dr. Sarah Chen — no spam, no supplement ads, just the data.

Join 4,200+ men · Completely private · Unsubscribe anytime